Clinical Trial Update: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of multiple doses of CFZ533 in Sjögren's syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjögren Syndrome | Phase 2 | Status: COMPLETED